<DOC>
	<DOCNO>NCT03074786</DOCNO>
	<brief_summary>Participants randomize ( 1:1 ) one two sequence vaginal ring ( VR ) contain 25mg dapivirine insert monthly 24 week 200 mg FTC/300 mg TDF oral tablet take daily 24 week . After complete randomized sequence two study product use period , participant select two study product use final 24 week trial . Participants able choose either neither study product every 4 week third product use period .</brief_summary>
	<brief_title>Reversing Epidemic Africa With Choices HIV Prevention ( REACH )</brief_title>
	<detailed_description>The MTN-034/IPM 045 trial multi-site , randomize , two-sequence , three-period , open-label , crossover Phase 2a trial . Young adult ( 18-21 year old ) adolescent ( 16-17 year old ) female participant enrol 2:1 ratio . All enrol participant use treatment regimen sequence . All participant randomly assign one two treatment regimen sequence use first two study product use period , able choose treatment regimen third study product use period . The total length follow-up approximately one half year include 72 week product use ( two 24-week period randomize treatment regimen one 24-week period freely choose treatment regimen ) plus additional week beyond Period 3 end visit collect data new worsen AEs .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>1 . Become Pregnant and/or use oral PrEP outside context study . 2 . At Screening Enrollment , positive HIV test . 1 . Age 16 21 year Enrollment , verify per site standard operation procedure . 2 . Able willing provide adequate locator information comply study procedural requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>